Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial-Reference-Cited by-同舟云学术

Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial

Published:2017 Issue:3 Volume:64 Page:269-281
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Bouchi Ryotaro¹,Nakano Yujiro¹,Fukuda Tatsuya¹,Takeuchi Takato¹,Murakami Masanori¹,Minami Isao¹,Izumiyama Hajime¹²,Hashimoto Koshi¹³,Yoshimoto Takanobu¹,Ogawa Yoshihiro¹

Affiliation:

1. Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

2. Center for Medical Welfare and Liaison Services, Tokyo Medical and Dental University, Tokyo, Japan

3. Department of Preemptive Medicine and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/64/3/64_EJ16-0449/_pdf

Reference40 articles.

1. 1. Nauck M (2016) Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab 18: 203-216.

2. 2. Du Q, Wang YJ, Yang S, Zhao YY, Han P (2014) Liraglutide for the treatment of type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Adv Ther 31: 1182-1195.

3. 3. Robinson LE, Holt TA, Rees K, Randeva HS, O’Hare JP (2013) Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 3: e001986.

4. 4. Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, et al. (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11: 1163-1172.

5. 5. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, et al. (2011) Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. Cardiovasc Diabetol 10: 109.

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Visceral and Hepatic Fat on Cardiometabolic Health;Current Cardiology Reports;2024-09-05

2. Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease;Hormones;2024-08-07

3. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials;Journal of Diabetes and its Complications;2024-06

4. Meta-analysis of the clinical efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease;Endocrine Journal;2024

5. Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age;Nutrients;2023-12-25